Risk assessment of recurrence of venous thromboembolism;Bewertung des Rezidivthrombose-risikos venöser Thromboembolien

Hamostaseologie

Volumn 31, Issue 1, 2011, Pages 7-13

  Lindhoff Last, E ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; GENE MUTATION; HUMAN; LUNG EMBOLISM; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; FEMALE; MALE; METHODOLOGY; PREVALENCE; SEX DIFFERENCE;

FEMALE; HUMANS; MALE; PREVALENCE; RECURRENCE; RISK ASSESSMENT; SEX FACTORS; VENOUS THROMBOEMBOLISM;

EID: 79952565601     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1144     Document Type: Review

References (36)

1. Douketis JD, Gu CS, Schuman S et al. The risk of fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 14: 766-774. (Pubitemid 351664441)
2. Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - a population-based cohort study. Arch Intern Med 2000; 160: 761-768. (Pubitemid 30165236)
3. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-based clinical practice guidelines. Chest 2008; 133: 454S-545S.
4. Hach-Wunderle V, Blättler W, Gerlach H et al. Interdisziplinäre S2-Leitlinie: Diagnostik und Therapie der Bein- und Beckenvenentrhombose und der Lungenembolie. VASA 2010; 66 (Suppl 66): 1-39.
5. Lijering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. BJH 2010; 149: 824-833.
6. Schulman S, Rebecca J, Beyth RJ et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians, Evidence-based clinical practice guidelines. Chest 2008; 133 (Suppl 6): 257S-298S.
7. Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
8. Pini M, Aiello S, Manotti et al. Low molecular weight heparin versus warfarin in the prevention of recurrence after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197. (Pubitemid 24251278)
9. Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007; 92: 199-205.
10. Eichinger S, Minar E, Bialonczyk C et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071-1074. (Pubitemid 37430448)
11. Palareti G, Legnani C, Cosmi B et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12. (Pubitemid 34092568)
12. Palareti G, Legnani C, Cosmi B et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in car riers of congenital thrombophilia. Circulation 2003; 108: 313-318. (Pubitemid 36899022)
13. Palareti G, Cosmi B, Legnani C et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-1789. (Pubitemid 44631361)
14. Bruinstroop E, Klok FA, Van de Ree MA et al. Elevated D-dimer levels predict recurrence in patients of idiopathic venous thromboembolism. A metaanalysis. J Thromb Haemost 2009; 7: 611-618.
15. Cosmi B, Legnani C, Tosetto A et al. PROLONG Investigators. Usefulness of repeated D-dimer testing after stopping anticoagulaition for a first episode of unprovoked venous thromboembolis. Blood 2010; 115: 481-488.
16. Young L, Ockelford P, Milne D et al. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4: 1919-1924. (Pubitemid 44226769)
17. Siragusa S, Malato A, Anastasio R et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis. The duration of anticoagulation based on compression ultrasonography (DACUS) study. Blood 2008; 112: 511-515.
18. Prandoni P, Prins MH, Lensing AWA et al. AESOPUS Investigators. Residual thrombosis on ultrasound to guide the duration of anticoagulation in patients with deep venous thrombosis. Ann Intern Med 2009; 150: 577-585.
19. Anderson JFA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107: 9-16.
20. Akl EA, Barba M, Rohilla S et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane database Syst Rev 2008: CD006650.
21. Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210 mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114. (Pubitemid 350144218)
22. Lijfering WM, Middeldorp S, Veeger NJ et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121: 1706-1712.
23. Taliani MR, Becattini C, Agnelli G et al. WODIT Investigators. Duration of anticoagulant treatment and recurrence of venous thromboembolismin patients with and without thrombophilic abnormalities. Thromb Haemost 2009; 101: 596-598.
24. Cohn D, Vansenne F, de Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database of systematic reviews 2009; 1: CD007069.
25. Brouwer JL, Lijfering WM, Ten Kate MK et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C and antithrombin. Thromb Haemost 2009; 101: 93-99.
26. SchulmanS, Lindmarker P, Homstrom M et al. Postthrombotic syndrome, recurrence and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4: 734-742.
27. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-338. (Pubitemid 28211022)
28. Pengo V, Ruffatti A, Legnani C et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
29. Palla A, Ribas C, Rossi G et al. The clinical course of pulmonary embolism patients anticoagulated for 1 year: results of a prospective observational, cohort study. J Thromb Haemost 2010; 8: 69-74.
30. Baglin T, Douketis J, Tosetto A et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis. J Thromb Haemost 2010; in press.
31. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004; 2: 2152-2155. (Pubitemid 40185775)
32. Kyrle PA, Minar E, Bialonczyk C et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-2563.
33. McRae S, Tran H, Schulman S et al. Effect of patient's sex on risk of recurrent venous thromboembolism: a metaanalysis. Lancet 2006; 368: 371-378. (Pubitemid 44108120)
34. Cosmi B, Legnani C, Tosetto A et al. PROLONG investigators. Sex, age and normal pot-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost 2010; 8: 1933-1942.
35. Christiansen SC, Lijfering WM, Helmerhorst FM et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 2010: 8: 2159-2168.
36. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism The Vienna prediction model. Circulation 2010; 121: 1630-1636.